Geopolitical disruption and war-related cost inflation
Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.
CIPLA / Q4-FY26 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Lanreotide supply disruption and remediation uncertainty
Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.
Indore facility regulatory overhang
Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.
Execution risk in US respiratory launches
Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance.